Abstract
Recent exciting advances have been made in identifying potential molecular markers in sputum which may soon be ready for validation trials to indicate high risk for lung cancer, especially central airway squamous cell lung cancer. Hopefully, a set of biomarkers will be identified with higher sensitivity, specificity, and enough lead-time compared to traditional cytopathology to justify endobronchial evaluation and local therapy to help reduce lung-cancer mortality in high-risk patients.
| Original language | English |
|---|---|
| Pages (from-to) | S21-S27 |
| Journal | Lung Cancer |
| Volume | 45 |
| Issue number | SUPPL. 2 |
| DOIs | |
| State | Published - Aug 2004 |
| Externally published | Yes |
Keywords
- Biological markers
- Non-small-cell lung carcinoma
- Sputum